tetano
Editor, Senior Moderator
Nat Commun
. 2022 Aug 9;13(1):4677.
doi: 10.1038/s41467-022-32149-8.
Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses
Norbert Pardi[SUP] 1 [/SUP], Juan Manuel Carreño[SUP] 2 3 [/SUP], George O'Dell[SUP] 2 [/SUP], Jessica Tan[SUP] 2 4 [/SUP], Csaba Bajusz[SUP] 5 6 [/SUP], Hiromi Muramatsu[SUP] 5 [/SUP], Willemijn Rijnink[SUP] 2 [/SUP], Shirin Strohmeier[SUP] 2 [/SUP], Madhumathi Loganathan[SUP] 2 3 [/SUP], Dominika Bielak[SUP] 2 3 [/SUP], Molly M H Sung[SUP] 7 [/SUP], Ying K Tam[SUP] 7 [/SUP], Florian Krammer[SUP] 8 9 [/SUP], Meagan McMahon[SUP] 10 [/SUP]
Affiliations
Abstract
Messenger RNA (mRNA) vaccines represent a new, effective vaccine platform with high capacity for rapid development. Generation of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is a necessity for reducing influenza-associated morbidity and mortality. Here we focus on the development of a universal influenza B virus vaccine based on the lipid nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) platform. We evaluate vaccine candidates based on different target antigens that afford protection against challenge with ancestral and recent influenza B viruses from both antigenic lineages. A pentavalent vaccine combining all tested antigens protects mice from morbidity at a very low dose of 50 ng per antigen after a single vaccination. These findings support the further advancement of nucleoside-modified mRNA-LNPs expressing multiple conserved antigens as universal influenza virus vaccine candidates.
. 2022 Aug 9;13(1):4677.
doi: 10.1038/s41467-022-32149-8.
Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses
Norbert Pardi[SUP] 1 [/SUP], Juan Manuel Carreño[SUP] 2 3 [/SUP], George O'Dell[SUP] 2 [/SUP], Jessica Tan[SUP] 2 4 [/SUP], Csaba Bajusz[SUP] 5 6 [/SUP], Hiromi Muramatsu[SUP] 5 [/SUP], Willemijn Rijnink[SUP] 2 [/SUP], Shirin Strohmeier[SUP] 2 [/SUP], Madhumathi Loganathan[SUP] 2 3 [/SUP], Dominika Bielak[SUP] 2 3 [/SUP], Molly M H Sung[SUP] 7 [/SUP], Ying K Tam[SUP] 7 [/SUP], Florian Krammer[SUP] 8 9 [/SUP], Meagan McMahon[SUP] 10 [/SUP]
Affiliations
- PMID: 35945226
- DOI: 10.1038/s41467-022-32149-8
Abstract
Messenger RNA (mRNA) vaccines represent a new, effective vaccine platform with high capacity for rapid development. Generation of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is a necessity for reducing influenza-associated morbidity and mortality. Here we focus on the development of a universal influenza B virus vaccine based on the lipid nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) platform. We evaluate vaccine candidates based on different target antigens that afford protection against challenge with ancestral and recent influenza B viruses from both antigenic lineages. A pentavalent vaccine combining all tested antigens protects mice from morbidity at a very low dose of 50 ng per antigen after a single vaccination. These findings support the further advancement of nucleoside-modified mRNA-LNPs expressing multiple conserved antigens as universal influenza virus vaccine candidates.